Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site

Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site

Thumbnail Image
Download
Name

s41467-023-42098-5.pdf

Description
Published version
Size

5.34 MB

Format

Adobe PDF

Checksum (MD5)

a4bb03f34edec240aa4f7a6982bb733d

sword-2025-02-18T23:31:02.original.xml (130 B)
Original SWORD entry document
Author(s)
Banach, Bailey B
•
Pletnev, Sergei
•
Olia, Adam S
•
Xu, Kai
•
Zhang, Baoshan
•
Rawi, Reda
•
Bylund, Tatsiana
•
Doria-Rose, Nicole A
•
Nguyen, Thuy Duong
•
Fahad, Ahmed S
more
Date Issued
2023
Journal
Nature Communications
Publisher
Springer Science and Business Media LLC
Citation
Banach, B.B., Pletnev, S., Olia, A.S. et al. Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site. Nat Commun 14, 7593 (2023).
Version
Final published version
Abstract
The HIV-1 fusion peptide (FP) represents a promising vaccine target, but global FP sequence diversity among circulating strains has limited anti-FP antibodies to ~60% neutralization breadth. Here we evolve the FP-targeting antibody VRC34.01 in vitro to enhance FP-neutralization using site saturation mutagenesis and yeast display. Successive rounds of directed evolution by iterative selection of antibodies for binding to resistant HIV-1 strains establish a variant, VRC34.01_mm28, as a best-in-class antibody with 10-fold enhanced potency compared to the template antibody and ~80% breadth on a cross-clade 208-strain neutralization panel. Structural analyses demonstrate that the improved paratope expands the FP binding groove to accommodate diverse FP sequences of different lengths while also recognizing the HIV-1 Env backbone. These data reveal critical antibody features for enhanced neutralization breadth and potency against the FP site of vulnerability and accelerate clinical development of broad HIV-1 FP-targeting vaccines and therapeutics.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Ragon Institute of MGH, MIT and Harvard
Terms of Use
Creative Commons Attribution
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/158240
DOI of Published Version
https://doi.org/10.1038/s41467-023-42098-5
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.